Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy by Mehran, Roxana et al.
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bjectives In this substudy of the ACUITY (Acute Catheterization and Urgent Intervention Triage
trategY) trial, we investigated the relationship between chronic kidney disease (CKD) and clinical
utcomes, and compared the safety and efﬁcacy of bivalirudin monotherapy versus heparin plus a
lycoprotein IIb/IIIa inhibitor (GPI).
ackground CKD is an important predictor of prognosis in the general population. The outcomes
f patients with CKD and acute coronary syndromes (ACS) have not been well studied.
ethods In the ACUITY study, 13,819 patients with moderate- and high-risk ACS undergoing an
arly, invasive strategy were randomly assigned to 1 of 3 antithrombin regimens: a heparin plus a
PI, bivalirudin plus a GPI, or bivalirudin monotherapy. CKD (creatinine clearance 60 ml/min) was
resent in 2,469 (19.1%) of 12,939 randomized patients with baseline creatinine clearance data.
esults Patients with CKD had worse 30-day and 1-year clinical outcomes than those with normal
enal function. There were no signiﬁcant differences between bivalirudin monotherapy and heparin
lus a GPI in rates of 30-day composite ischemia (11.1% vs. 9.4%, p  0.27) and net clinical adverse
utcomes (16.1% vs. 16.9%, p  0.65). There was remarkably less major bleeding (6.2% vs. 9.8%,
 0.008) at 30 days, but no signiﬁcant difference in 1-year composite ischemia (22.0% vs. 18.9%,
 0.10) or mortality (7.1% vs. 7.3%, p  0.96).
onclusions In patients with ACS, CKD is associated with higher 30-day and 1-year adverse event
ates. Compared with heparin plus a GPI, the use of bivalirudin monotherapy in patients with
KD results in nonstatistically different ischemic outcomes, but signiﬁcantly less 30-day major
leeding. (J Am Coll Cardiol Intv 2009;2:748–57) © 2009 by the American College of Cardiology
oundation
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749hronic kidney disease (CKD) in patients with coronary artery
isease is strongly associated with reduced survival and an elevated
ncidence of bleeding complications after percutaneous coronary
ntervention (PCI) and coronary artery bypass grafting (CABG)
1–9). Thus, considerable research has been conducted to inves-
igate optimal adjunctive antithrombotic medications to suppress
leeding complications while maintaining anti-ischemic activity in
hese patients (3–5,7,10,11). Bivalirudin is a direct thrombin
nhibitor whose clearance is less dependent on renal function than
eparin, hirudin, or glycoprotein IIb/IIIa inhibitors (GPIs) (12).
urthermore, because thrombin activity is increased in patients
ith CKD, the pharmacologic properties of bivalirudin support
he possibility of particular benefit in patients with renal insuffi-
iency (13).
The ACUITY (Acute Catheterization and Urgent Interven-
ion Triage strategY) study demonstrated that in patients with
oderate- and high-risk acute coronary syndromes (ACS) under-
oing an early invasive strategy, bivalirudin monotherapy with
rovisional use of a GPI was associated with a comparable rate of
schemic events at 30 days and 1 year, but with a significantly
ower incidence of 30-day major bleeding than heparin (either
nfractionated heparin [UFH] or enoxaparin) plus a GPI (14,15).
n this substudy of the ACUITY trial, we investigated the
elationship between CKD and clinical outcomes at 30 days and
year, with a focus on the safety and efficacy of contemporary
ntithrombotic regimens in patients with ACS and baseline CKD
s measured by the clinical end points used in the original study.
ethods
atient population, randomization, and study protocol. The
esign and results of the ACUITY trial have been previ-
usly published (14–17). Briefly, 13,819 patients with
oderate- and high-risk ACS undergoing an early, invasive
anagement strategy were randomly assigned 1  1  1 in
n open-label fashion to 1 of 3 antithrombin regimens
tarting immediately after randomization: a heparin (UFH
r enoxaparin) plus a GPI (the control group), bivalirudin
lus a GPI, or bivalirudin monotherapy with the provisional
bail-out) use of GPIs permitted only for limited pre-
pecified indications. Patients with baseline creatinine clear-
nce (CrCl) 30 ml/min were excluded from enrollment.
onsultant for Lilly and Daichi-Sankyo and is a member of the Speakers’ Bureaus of
anofi-Aventis, Astra Zeneca, and the Medicines Company. Dr. Kirtane is a member of
he Speakers’ Bureau of The Medicines Company. Dr. Feit is a consultant for the
edicines Company and a shareholder of Millennium Pharmaceuticals, Johnson &
ohnson, and The Medicines Company. Dr. Manoukian is a consultant, member of the
peakers’ Bureau, and has received honoraria from The Medicines Company. Dr.
brahimi is a consultant and member of the Speakers’ Bureau of The Medicines
ompany. Dr. Ohman is a consultant for The Medicines Company, Inovise, Savacor,
iposcience, Response Biomedical, Datascope, and Abioed; is in receipt of research grants
rom Sanofi-Aventis, Bristol-Myers Squibb, Eli Lilly, Berlex, and Millennium Pharma-
euticals; is on the Speakers’ Bureau of Schering Plough and CV Therapeutics; and is a
M
aUFH was administered as an intravenous bolus of 60 IU/kg
lus an infusion of 12 IU/kg/h to achieve an activated partial
hromboplastin time of 50 to 75 s before angiography and an
ctivated clotting time of 200 to 250 s for patients undergoing
CI. Enoxaparin 1 mg/kg subcutaneously was administered at
andomization and every 12 h thereafter until angiography. An
dditional intravenous bolus of 0.3 mg/kg or 0.75 mg/kg was
dministered before PCI if the most recent subcutaneous dose
ad been given8 h or16 h earlier, respectively. Bivalirudin
as first administered upon presentation to the hospital with
n intravenous bolus of 0.1 mg/kg and an infusion of 0.25
g/kg/h. Before PCI, an additional intravenous bolus of 0.5
g/kg was administered, and the infusion was increased to
.75 mg/kg/h. Antithrombin agents were discontinued per
rotocol at the end of the procedure.
Patients assigned to a GPI arm were randomized again in a
 2 factorial design to either upstream GPI initiation in all
atients immediately after ran-
omization or to deferred GPI
nitiation for selective use in PCI
atients only starting in the cath-
terization laboratory. As per
ood and Drug Administration-
pproved labeling, either eptifi-
atide or tirofiban was permitted
or upstream use and either epti-
batide or abciximab was permit-
ed for deferred selective use. Per
tudy protocol, dosages of all
PIs were as per the package
nsert and were adjusted for calcu-
ated glomerular filtration rate.
Coronary angiography was re-
uired within 72 h of randomiza-
ion, with subsequent triage to
CI, CABG, or medical manage-
ent as per standard of care. As-
irin (300 to 325 mg orally or 250 to 500 mg intravenously)
as administered before angiography. Clopidogrel dosing and
iming were left to the discretion of the investigators, but in
atients undergoing PCI, 300 mg of clopidogrel was required
n all cases no later than 2 h after PCI. Clopidogrel 75 mg daily
as recommended for 1 year in all patients after PCI and 75 to
hareholder of Inovise, Savacor, and Medtronic. Dr. White is in receipt of research grants
rom Sanofi-Aventis, Eli Lilly, Merck Sharpe & Dohme, The Medicines Company,
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Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CABG  coronary artery
bypass grafting
CI  confidence interval
CKD  chronic kidney
disease
CrCl  creatinine clearance
GPI  glycoprotein IIb/IIIa
inhibitor
OR  odds ratio
PCI  percutaneous
coronary intervention
UFH  unfractionated
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CKD and ACS
75025 mg of aspirin daily was recommended indefinitely. The
tudy was approved by the institutional review board or ethics
ommittee at each participating center, and all patients signed
ritten, informed consent. The authors had full access to the
ata and take responsibility for its integrity. All authors have
ead and agreed to the manuscript as written.
nd points and statistical methods. The ACUITY trial was
owered for 3 primary 30-day end points: 1) composite
schemia, defined as death from any cause, myocardial infarc-
ion, or unplanned revascularization for ischemia; 2) major
leeding (non-CABG related), defined as intracranial, retro-
eritoneal, or intraocular bleeding, access site hemorrhage
equiring intervention, hematoma 5 cm in diameter, reduc-
ion in hemoglobin of 4 g/dl without or 3 g/dl with an
vert bleeding source, reoperation for bleeding, or blood
roduct transfusion; and 3) net clinical outcome (composite
schemia or major bleeding) (16). Composite ischemia and
ortality were assessed out to 1 year. A clinical events
ommittee blinded to treatment assignment adjudicated all
0-day and 1-year primary end point events using original
ource documents.
CKD was defined as a calculated CrCl of60 ml/min using
he Cockcroft-Gault equation based on admission laboratory
nalysis (before any contrast media exposure). The present
nalysis examined baseline features and 30-day and 1-year
utcomes: 1) of patients with versus those without CKD (CrCl
60 ml/min); and 2) by randomized group comparing each of
he bivalirudin arms against the heparin plus GPI reference
rm within the CKD cohort. In addition, a separate analysis
as conducted in order to assess the impact of potential excess
ose of study medication in CKD patients. Excess-dose
atients were defined as those with: 1) CrCl 50 ml/min
reated with more than the recommended dose of eptifibatide
Figure 1. Enrollment and Randomization of the Patients in the ACUITY Tria
Patient ﬂow in the ACUITY (Acute Catheterization and Urgent Intervention Tria
(CrCl), and randomization to 1 of 3 antithrombotic regimens (heparin plus a g
with the provisional [bail-out] use of GPIs).99 m/kg initial bolus or1.1 m/kg/min initial infusion);
nd 2) CrCl 30 ml/min and receiving more than the
ecommended dose of enoxaparin (0.55 mg/kg subcutane-
usly every 12 h or 0.165 mg/kg intravenously every 12 h).
lthough CrCl 30 ml/min was an exclusion criterion, a few
uch patients were enrolled. Only the first dose of enoxaparin
fter randomization was considered.
While CKD was a pre-specified subgroup for analysis, the
CUITY trial was not powered for formal superiority or
oninferiority testing of this or any other subgroup. All
nalyses are by intention to treat. Chi-square tests were used
or categorical variables. Continuous variables were tested
sing Wilcoxon rank sum test. Medians and interquartile
anges are presented for continuous variables. Follow-up anal-
sis was performed using time-to-event data (for which pa-
ients were censored at the time of withdrawal from the study
r at last follow-up) and were compared with the log-rank test.
Multivariable logistic regression analysis was performed
o determine the predictors of composite ischemia and
ajor bleeding. Potential predictors were selected using
tepwise, forward, and backward procedures. Covariates
ere entered into the model with a p value 0.15 and
etained with a p value 0.10. The final model includes all
redictors that were selected by at least 1 of the 3 selection
rocedures. The p values, odds ratios (ORs), and corre-
ponding 2-sided 95% confidence interval (CI) for predic-
ors are presented. All statistical analyses were performed by
AS V8.2 (SAS Institute Inc., Cary, North Carolina).
esults
KD was present in 2,469 (19.1%) of 12,939 randomized
atients with baseline CrCl data (Fig. 1). Baseline CrCl
ategY) trial: enrollment, stratiﬁcation based on baseline creatinine clearance
otein IIb/IIIa inhibitor [GPI], bivalirudin plus a GPI, or bivalirudin monotherapyl
ge str
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751ata were missing for 880 patients (6.8%). Baseline charac-
eristics and treatment strategies by renal function are
etailed in Table 1. Compared with patients without CKD,
atients with CKD were more likely to be older, women,
nemic, to have a history of hypertension or hyperlipidemia,
o have had a previous myocardial infarction, to have
ndergone prior CABG surgery to be classified as high risk
pon enrollment (defined as elevated creatine kinase-MB or
roponin levels and/or ST-segment deviation), and to have
T-segment deviation. Patients without CKD were more
ikely to be smokers, to have higher body weight, and to
ave a family history of coronary artery disease. Patients
ithout CKD were more likely to undergo PCI whereas
hose with CKD were more often medically managed.
roportion of patients who received enoxaparin did not
iffer significantly between groups with and without CKD
22.5% vs. 23.5%, p  0.16), though patients who received
noxaparin 8 h before PCI were slightly more common in
he CKD group (69.9% vs. 65.9%, p  0.06) while patients
ho received enoxaparin 16 h before PCI were less
ommon in the CKD group (25.0% vs. 29.2%, p  0.04).
Table 1. Baseline Characteristics and Treatment Stra
CrCl <60 ml/m
(N  2,4
n/N (%
Age (yrs), median (range) 75 (29–9
Age 75 yrs 1,346/2,469
Weight (kg), median (IQR) 71 (63.0, 8
Women 1,158/2,469
Diabetes 711/2,453
Current smoker 355/2,409
Prior myocardial infarction 815/2,397
Prior PCI 975/2,442
Prior CABG 573/2,461
Family history of CAD 886/2,016
Hypertension 1,912/2,461
Anemia* 720/2,438
CrCl (ml/min), median (range) 48.7 (40.8–
Hyperlipidemia 1,467/2,443
High risk† 1,758/2,384
CK-MB/troponin elevation 1,391/2,326
ST-segment deviation 1,015/2,468
Treatment strategy
PCI 1,352/2,469
CABG 271/2,469
Medical management 846/2,469
Prior thienopyridine
exposure‡
1,618/2,414
*Anemia was defined using theWorld Health Organization criteria (hem
as either creatine kinase (CK)-MB or troponin elevation, or ST-segment
before randomization, any dose before angiography (in coronary arter
coronary intervention (PCI) for all PCI patients.
CAD coronary artery disease; CKD chronic kidney disease; CrClinterquartile range.enal function and outcome. Table 2 presents 30-day and
-year clinical outcome data in patients with versus without
KD. Patients with CKD compared with those without had
ignificantly higher rates of composite ischemia (10.8% vs.
.0%, p  0.0001) and major bleeding (9.2% vs. 3.6%,
 0.0001) with a resultant increase in net clinical outcomes
17.5% vs. 9.9%, p 0.0001). With respect to the components
f the composite ischemic end point, patients with CKD had
ignificantly increased rates of death, myocardial infarction,
nd unplanned revascularization. Non-CABG minor bleeding,
hrombolysis In Myocardial Infarction (TIMI) major and
inor bleeding, and thrombocytopenia also occurred signifi-
antly more frequently in patients with versus without CKD.
atients with CKD were significantly more likely to experience
etroperitoneal bleeding, access site hemorrhage, hematoma
5 cm in diameter, a hemoglobin drop of 4 g/dl without
vert bleeding, or 3 g/dl with overt bleeding, and to require
lood product transfusions. At 1 year, rates of composite
schemia (21.6% vs. 14.4%) and mortality (7.9% vs. 2.8%) were
ignificantly higher (both p  0.001) in patients with CKD
ompared with those without CKD (Table 2).
s by Renal Function
D) CrCl >60 ml/min
(N  10,470)
n/N (%) p Value
60 (20–90) 0.0001
932/10,470 (8.9) 0.0001
86 (76.3, 98.0) 0.0001
2,696/10,470 (25.7) 0.0001
2,870/10,404 (27.6) 0.16
3,351/10,306 (32.5) 0.0001
3,113/10,252 (30.4) 0.0005
4,016/10,394 (38.6) 0.24
1,708/10,454 (16.3) 0.0001
4,944/9,139 (54.1) 0.0001
6,707/10,431 (64.3) 0.0001
1,432/10,315 (13.9) 0.0001
95.8 (77.7–118.8) 0.0001
5,778/10,257 (56.3) 0.0009
7,233/10,109 (71.6) 0.03
5,877/9,919 (59.2) 0.63
3,509/10,467 (33.5) 0.0001
5,994/10,470 (57.2) 0.02
1,172/10,470 (11.2) 0.76
3,304/10,470 (31.6) 0.009
6,542/10,349 (63.2) 0.0004
in13 g/dl for men and12 g/dl for women); †high risk was defined
on; ‡thienopyridine exposure: either chronic use, any administration
s grafting [CABG] andmedically managed patients), or percutaneous
inine clearance, calculated using the Cockcroft-Gault equation; IQRtegie
in (CK
69)
)
5)
(54.5)
0.8)
(46.9)
(29.0)
(14.7)
(34.0)
(39.9)
(23.3)
(43.9)
(77.7)
(29.5)
55.1)
(60.0)
(73.7)
(59.8)
(41.1)
(54.8)
(11.0)
(34.3)
(67.0)
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752As seen in Table 3, bleeding and adverse ischemic events
ccurred more frequently with decreasing renal function.
atients with CrCl 30 or 30 to 59 ml/min had signifi-
antly higher rates of major bleeding and ischemic events at
0 days and 1 year compared with those patients with CrCl
0 to 89 or 90 ml/min.
Table 2. Clinical Outcomes at 30 Days and 1 Year by
30 days
Net clinical outcome (primary end point)
Composite ischemia (primary end point)
Death (any cause)
MI
Q-wave
Non–Q-wave
Death or MI
Unplanned revascularization for ischemia
Major bleeding (non–CABG-related) (primary end point)
Intracranial
Retroperitoneal
Intraocular
Access site
Hematoma 5 cm
Hemoglobin decrease 3 g/dl with overt source
Reoperation for bleed
Blood transfusion
Minor bleeding (non–CABG-related)*
TIMI scale bleeding
TIMI major bleeding
TIMI minor bleeding
Thrombocytopenia†
1 yr
Composite ischemia
Mortality
*Ecchymoses, epistaxis, gastrointestinal, genitourinary, puncture site,
in patients without baseline thrombocytopenia.
MImyocardial infarction; TIMI Thrombolysis In Myocardial Infa
Table 3. Outcomes of Patients With CKD by CrCl
CrCl <30 ml/min
(N  189)
n (%)
C
30 days
Net clinical outcome 36 (19.0)
Composite ischemia 24 (12.7)
Major bleeding (non–CABG-related) 17 (9.0)
1 yr
Composite ischemia 41 (21.7)
Mortality 20 (10.6)Abbreviations as in Table 1.mpact of antithrombotic regimen in patients with CKD.
aseline demographic, clinical, and procedural characteris-
ics among the 3 randomized groups were similar except for
ean serum CrCl values, which were lowest in the biva-
irudin monotherapy group (45.4 12.3 ml/min) compared
ith patients in the heparin plus GPI group (47.3  10.8
l Function
l <60 ml/min (CKD)
(N  2,469)
n (%)
CrCl >60 ml/min
(N  10,470)
n (%) p Value
433 (17.5) 1,036 (9.9) 0.0001
267 (10.8) 729 (7.0) 0.0001
75 (3.0) 118 (1.1) 0.0001
164 (6.6) 504 (4.8) 0.0002
31 (1.3) 108 (1.0) 0.33
135 (5.5) 397 (3.8) 0.0002
7.6 10.0 9.4
76 (3.1) 247 (2.4) 0.04
226 (9.2) 381 (3.6) 0.0001
1 (0.1) 6 (0.1) 0.75
21 (0.9) 34 (0.3) 0.0003
1 (0.1) 1 (0.1) 0.27
19 (0.8) 43 (0.4) 0.02
70 (2.8) 154 (1.5) 0.0001
87 (3.5) 127 (1.2) 0.0001
3 (0.1) 7 (0.1) 0.38
143 (5.8) 149 (1.4) 0.0001
601 (24.3) 1,851 (17.7) 0.0001
243 (9.8) 499 (4.8) 0.0001
68 (2.8) 124 (1.2) 0.0001
234 (9.5) 471 (4.5) 0.0001
345 (14.0) 1,088 (10.4) 0.0001
533 (21.6) 1,504 (14.4) 0.001
195 (7.9) 291 (2.8) 0.001
ricardium, pulmonary, or other; †platelet count150,000 cells/mm3
ther abbreviations as in Table 1.
to 59 ml/min
 2,280)
n (%)
CrCl 60 to 89 ml/min
(N  4,462)
n (%)
CrCl >90 ml/min
(N  6,008)
n (%)
97 (17.4) 507 (11.4) 529 (8.8)
43 (10.7) 354 (7.9) 375 (6.2)
09 (9.2) 196 (4.4) 185 (3.1)
92 (21.6) 688 (15.4) 816 (13.6)
75 (7.7) 190 (4.3) 101 (1.7)Rena
CrC
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753l/min, p 0.005) and patients in the bivalirudin plus GPI
roup (46.0  11.5 ml/min, p  0.67 and p  0.01 as
ompared with bivalirudin alone and heparin plus GPI
roups, respectively). At 30 days, patients with CKD treated
ith bivalirudin alone compared with those treated with
eparin plus a GPI had a remarkably reduced rate of
on-CABG major bleeding (6.2% vs. 9.8%, p  0.008),
hough somewhat higher rates of composite ischemia
11.1% vs. 9.4%, p  0.27) (Table 4). None of the
ndividual end points of composite ischemia differed signif-
cantly between patients treated with bivalirudin mono-
herapy and those treated with heparin plus a GPI (Table
). This was also true with regard to 30-day composite
eath or myocardial infarction. By formal interaction test-
ng, there was no significant interaction between the pres-
nce or absence of CKD; antithrombin randomization; and
he occurrence of composite ischemia, major bleeding, or
et clinical outcomes (p values for interaction  0.49, 0.25,
nd 0.42, respectively). Excluding access site hematoma still
esulted in significant reduction of major bleeding rates in
avor of bivalirudin compared with heparin plus a GPI
5.6% vs. 8.5%, p  0.024). Non-CABG minor bleeding,
Table 4. Clinical Outcomes at 30 Days in Patients With CKD by Randomize
Heparin
(UFH or Enoxaparin)
Plus GPI
(N  826)
n (%)
B
(
Net clinical outcome (primary end point) 140 (16.9)
Composite ischemia (primary end point) 78 (9.4)
Death from any cause 20 (2.4)
Myocardial infarction 49 (5.9)
Q-wave 9 (1.1)
Non–Q-wave 40 (4.8)
Death or myocardial infarction 63 (7.6)
Unplanned revascularization for ischemia 22 (2.7)
Major bleeding (non–CABG-related) (primary end point) 81 (9.8)
Intracranial 1 (0.1)
Retroperitoneal 8 (1.0)
Access site‡ 35 (4.2)
Hemoglobin decrease 3 g/dl with overt source 35 (4.2)
Hemoglobin decrease 4 g/dl with no overt source 8 (1.0)
Blood transfusion 52 (6.3)
Reoperation for bleed 1 (0.1)
Minor bleeding (non–CABG-related)§ 235 (28.5)
TIMI scale bleeding 87 (10.5)
TIMI major bleeding 31 (3.8)
TIMI minor bleeding 84 (10.2)
Thrombocytopenia 121 (14.6)
*p1 comparison between bivalirudin plus glycoprotein IIb/IIIa inhibitor (GPI) and heparin plus GPI
hematoma5 cm at the puncture site; §ecchymoses, epistaxis, gastrointestinal, genitourinary, pun
baseline thrombocytopenia.
CI confidence interval; UFH unfractionated heparin; other abbreviations as in Tables 1 and 2IMI major bleeding, TIMI minor bleeding, access site memorrhage, hemoglobin decreases of 3 g/dl with overt
leeding, and blood transfusions all occurred significantly
ess frequently in the bivalirudin alone arm compared with
he heparin plus GPI arm. At 1 year, rates of composite
schemia were slightly but nonsignificantly higher in the
ivalirudin monotherapy arm versus the heparin plus GPI
rm (22.0% vs. 18.9%, p  0.10). However, rates of hard
linical end points including mortality (7.1% vs. 7.3%, p 
.96), Q-wave myocardial infarction (9.9% vs. 8.5%, p 
.29), and the composite of death or myocardial infarction
15.6% vs. 13.9%, p  0.33) were not significantly different
etween the 2 arms (Fig. 2).
ssessment of dosing. We performed a separate analysis to
dentify and exclude any patients who may have received
ore than the recommended dose from the package insert
n order to determine if the overall results persisted. A total
f 428 patients (17%) with CKD and potential excess
osing as previously described were excluded from the
nalyses (204 patients in the heparin plus GPI group [25%],
08 patients in the bivalirudin plus GPI group [25%], and
6 patients in the bivalirudin monotherapy arm [2%]). In
he subset of correctly dosed patients, at 30 days, bivalirudin
atment Group
din
PI
24)
)
Risk Ratio
(95% CI) p1 Value*
Bivalirudin
Alone
(N  819)
n (%)
Risk Ratio
(95% CI) p2 Value†
.5) 1.15 (0.94–1.42) 0.17 132 (16.1) 0.95 (0.77–1.18) 0.65
.9) 1.26 (0.95–1.67) 0.11 91 (11.1) 1.18 (0.88–1.57) 0.27
) 1.40 (0.80–2.47) 0.24 27 (3.3) 1.36 (0.77–2.41) 0.29
) 1.23 (0.85–1.77) 0.27 55 (6.7) 1.13 (0.78–1.64) 0.51
) 0.29 8 (1.0) 0.82
) 0.38 47 (5.7) 0.42
.0) 1.30 (0.95–1.79) 0.10 77 (9.4) 1.23 (0.90–1.70) 0.20
) 1.37 (0.80–2.35) 0.26 24 (2.9) 1.10 (0.62–1.95) 0.74
.4) 1.16 (0.88–1.54) 0.29 51 (6.2) 0.64 (0.45–0.89) 0.008
) 0.32 0 (0.0) 0.32
) 0.49 2 (0.2) 0.06
) 0.99 12 (1.5) 0.0007
) 0.71 14 (1.7) 0.003
) 0.20 9 (1.1) 0.79
) 0.61 34 (4.2) 0.05
) 0.99 1 (0.1) 0.99
.3) 0.60 141 (17.2) 0.0001
.1) 0.11 48 (5.9) 0.0006
) 0.42 12 (1.5) 0.004
.9) 0.09 44 (5.4) 0.0003
.5) 0.49 113 (13.8) 0.62
comparison between bivalirudin alone and heparin plus GPI; ‡includes access site hemorrhage and
te, hemopericardium, pulmonary, or other; platelet count150,000 cells/mm3 in patients withoutd Tre
ivaliru
Plus G
N  8
n (%
161 (19
98 (11
28 (3.4
60 (7.3
14 (1.7
48 (5.8
82 (10
30 (3.6
94 (11
0 (0.0
11 (1.3
35 (4.2
38 (4.6
14 (1.7
57 (6.9
1 (0.1
225 (27
108 (13
25 (3.0
106 (12
111 (13
; †p2
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754imilar protection from composite ischemia (10.8% vs.
.0%, p 0.26) with significantly less major bleeding (6.1%
s. 9.0%, p  0.04). One-year results were concordant with
he overall findings, without any interaction between excess
osage and clinical outcome, and with no significant differ-
nces observed in composite ischemia (21.3% vs. 18.2%,
 0.11) or mortality (7.0% vs. 6.4%, p  0.61) among
hose treated with bivalirudin monotherapy versus heparin
lus a GPI.
actors associated with composite ischemia and major bleed-
ng in patients with CKD. A multivariable logistic regression
nalysis was performed to evaluate the impact of baseline
Figure 2. Ischemic Outcomes by Treatment Arm at 1 Year
One-year clinical outcomes by treatment group in renally impaired patients
displayed as hazard ratio (HR) (solid boxes) with 95% conﬁdence intervals
(CIs) (horizontal limit lines). GPI  glycoprotein IIb/IIIa inhibitor.
Figure 3. Multivariable Predictors of Major Bleeding at 30 Days
Multivariable analysis of the factors associated with 30-day major bleeding am
with 95% conﬁdence intervals (CIs) (horizontal limit lines). ECG  electrocardiogramharacteristics on composite ischemia and 30-day (non-
ABG related) major bleeding in all patients with CrCl
60 ml/min. Factors associated with composite ischemia
ncluded presence of ST-segment deviation 1 mm (OR:
.61 [95% CI: 1.23 to 2.11], p  0.0005), prior cerebro-
ascular accident (stroke or transient ischemic attack) (OR:
.79 [95% CI: 1.19 to 2.67], p  0.005), positive cardiac
arkers (OR: 1.58 [95% CI: 1.18 to 2.12], p  0.002), and
aseline anemia (OR: 1.51 [95% CI: 1.14 to 1.99], p 
.004), but did not include randomization to bivalirudin
ompared with heparin plus GPI (OR: 1.15 [95% CI: 0.83
o 1.60], p  0.54). Factors associated with major bleeding
ncluded baseline anemia, prior cerebrovascular accident,
iabetes mellitus, electrocardiogram changes, female gen-
er, and treatment with heparin plus the routine use of a
PI rather than bivalirudin monotherapy (Fig. 3).
iscussion
he main findings of this analysis of patients with
oderate- and high-risk non–ST-segment elevation ACS
ndergoing an early invasive management strategy are as
ollows: 1) treatment with bivalirudin monotherapy resulted
n significantly fewer 30-day bleeding complications with no
ignificant difference in either composite ischemia or mor-
ality at 30 days or 1 year compared with treatment with
eparin plus a GPI; and 2) the results were consistent after
atients who received excess dosages of either eptifibatide or
noxaparin were excluded from the analysis, providing
vidence that the reduced rate of major bleeding observed
ith bivalirudin monotherapy among patients with CKD is
ot driven by excess dosing in the heparin plus GPI arm.
ur findings are consistent with the overall results of the
atients with renal insufﬁciency, displayed as odds ratio (OR) (solid boxes)ong p
; GPI  glycoprotein IIb/IIIa inhibitor.
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755CUITY study in terms of the effect of bivalirudin mono-
herapy on composite ischemia, major bleeding, and net
linical outcomes at 30 days and 1 year (14,15).
KD and coronary artery disease. In agreement with previ-
us studies, the presence of CKD in this analysis was
ssociated with a significantly increased incidence of bleed-
ng complications at 30 days as well as an increased
ncidence of ischemic events and mortality at 30 days and 1
ear (2,5–7,9,18). This may, in part, be attributable to the
requent presence of comorbid conditions and more ad-
anced coronary artery disease in patients with CKD.
igh-risk characteristics such as older age, hypertension,
nemia, hyperlipidemia, elevated levels of cardiac biomark-
rs, and ST-segment changes were more common in pa-
ients with CKD. Increased systemic inflammation, height-
ned coagulation, and greater atheromatous plaque burden
ay also contribute to a higher risk of acute adverse events
19–22). Furthermore, just as in the CRUSADE (Can
apid Risk Stratification of Unstable Angina Patients
uppress Adverse Outcomes with Early Implementation of
he American College of Cardiology/American Heart As-
ociation Guidelines) registry (9), PCI in the ACUITY
tudy was used less frequently in patients with CKD than in
hose without CKD. Whether this contributed to the worse
rognosis in these patients is uncertain.
KD and bleeding complications. In the present study,
atients with CKD demonstrated a 3-fold increase in major
leeding complications. This excess bleeding risk may be
ttributed to functional abnormalities in platelets and coag-
lation in these patients (23). Therefore, when treating
atients with CKD presenting with non–ST-segment ele-
ation ACS, administration of the optimal antithrombotic
egimen should minimize the risk of hemorrhagic compli-
ations while providing sufficient protection from adverse
schemic events. In previous studies, both GPIs and biva-
irudin significantly decreased the risk of early ischemic or
hrombotic events in patients with ACS compared with
raditional heparin therapy (1,3,4,10,24,25), though an
ncreased bleeding risk was noted with GPIs in patients
ith CKD (1,3,25). The results of the present study,
emonstrating reduced major bleeding in patients with
KD randomized to bivalirudin monotherapy rather than
eparin plus a GPI, confirms the results of an earlier
eta-analysis (3). However, an important finding from this
nalysis is that bivalirudin was no more beneficial in patients
ith CKD when used in combination with a GPI. More-
ver, in the bivalirudin plus GPI arm, there was a trend
oward higher rates of 30-day composite ischemia (11.9%
s. 9.4%, p  0.11), major bleeding (11.4% vs. 9.8%, p 
.29), and net clinical outcome (19.5% vs. 16.9%, p  0.17)
ompared with the heparin plus GPI arm. Thus, physicians
hould be aware that the combination of bivalirudin and a
PI in patients with CKD may increase bleeding and gschemic adverse events, and should be administered only in
ail-out situations.
Higher, although not significantly so, rates of the com-
osite ischemic end point of death/myocardial infarction/
nplanned revascularization in the bivalirudin arm as op-
osed to the heparin plus GPI arm at 30-day and 1-year
ollow-up in this analysis deserves comment. Had more
atients been enrolled, it is possible that the difference
etween the 2 groups in rates of the composite ischemic end
oint would have been more apparent. Yet, hard clinical end
oints of death, myocardial infarction, or composite death/
yocardial infarction did not differ significantly between
he 2 groups, and by multivariable analysis composite
schemia was not associated with randomization to bivaliru-
in. Finally, given the fact that bleeding represents a short-
nd long-term mortality risk for non–ST-segment elevation
CS patients that is at least equivalent to that of ischemic
vents (26–28), preventing both ischemic and bleeding
omplications is important for optimizing patient outcomes.
For patients undergoing elective or urgent PCI, the
EPLACE-2 (Second Randomized Evaluation in PCI
inking Bivalirudin to Reduced Clinical Events) trial
howed that, among 886 patients with CKD, bivalirudin
onotherapy resulted in fewer major bleeding complica-
ions than heparin plus a GPI (3.2% vs. 7.1%, p  0.009),
ith no significant differences in 30-day rates of composite
schemia (5.1% vs. 7.1%, p  0.21) (10). And given the
revious finding in the CRUSADE trial that patients with
KD are less likely to receive American College of Cardi-
logy/American Heart Association guidelines-recommended
herapies due to the fear of bleeding complications, the present
tudy suggests that the use of bivalirudin plus bail-out GPI
with its reduction of bleeding risk) may permit more appro-
riate evidence-based use of PCI. This would potentially
mprove clinical outcomes in patients with NSTE-ACS and
KD.
Agents such as enoxaparin and eptifibatide are supposed
o be dose-adjusted for patients with CKD per current
ackage inserts. However, at the time the ACUITY trial
as enrolling, the package insert for enoxaparin did not
pecify dose adjustments. Clinical trials and large registries
ave raised concerns that, even with package-insert recom-
ended adjusted dosing, some patients were still potentially
t risk of receiving an excess dose of either enoxaparin,
ptifibatide, or both. This is an important consideration
ecause excess dosing may result in increased bleeding
omplications (29,30). For example, an analysis of the large
RUSADE registry (31) demonstrated that an excess dose
f enoxaparin—compared with a recommended dose—was
ignificantly associated with major bleeding (OR: 1.43; 95%
I: 1.18 to 1.75) and death (OR: 1.35; 95% CI: 1.03 to
.77). In the ACUITY trial, not only was bivalirudin less
requently associated with excess dosing (perhaps due to
reater adherence to the dosage chart of the investigational
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756gent), but it was also associated with similar overall results
fter exclusion of patients with excess dosing.
tudy limitations. Several limitations of the present analysis
ust be addressed. First, while CKD was a pre-specified
ubgroup for analysis, the ACUITY trial was not powered
or formal superiority or noninferiority testing of this or any
ther subgroup, so these results should be considered
xploratory (32). Nonetheless, this is the largest cohort of
atients with CKD enrolled in a prospective randomized
rial of patients with non–ST-segment elevation ACS.
econd, the precise mechanism of the association between
KD and a high rate of complications was not elucidated by
his analysis. Third, approximately 9% of patients in the
CUITY study who did not have baseline CrCl data were
ot included in this analysis. Finally, the ACUITY trial did
ot enroll patients with severe CKD (CrCl 30 ml/min or
hose requiring dialysis). Further study is required to deter-
ine the optimal anticoagulant regimen in patients with
hat degree of renal impairment.
onclusions
n summary, we found that in patients presenting with
oderate- and high-risk non–ST-segment elevation ACS
ndergoing an early invasive strategy, CKD was associated
ith an increased incidence of ischemic and bleeding
omplications and reduced 30-day and 1-year survival. In
hese patients, treatment with bivalirudin monotherapy
esulted in a significant reduction in major bleeding com-
lications at 30 days, and no significant difference in either
schemic complications or mortality at 30 days and 1 year
ompared with heparin plus the routine use of GPIs. These
ndings indicate that bivalirudin monotherapy is an accept-
ble alternative to heparin plus a GPI in patients with CKD.
eprint requests and correspondence: Dr. Roxana Mehran,
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